Pam78 contrast agent (Zaheer et al.,
Nature Biotech, 2001), a near-
infrared fluorescent small molecule
specfic for hydroxyapatite (HA).
(Click for larger image.)

The Frangioni Laboratory is invested heavily in 800 nm near-infrared (NIR) fluorescent contrast agent chemistry. We have developed robust methods for the preparation of heptamethine indocyanine NIR fluorophores conjugated to small molecules, peptides, and proteins, and continue to develop disease-specific contrast agents for optical imaging.

In addition to organic NIR fluorophores, a currently funded project focuses on the development of NIR quantum dots (fluorescent semiconductor nanocrystals) for tumor-targeting and cancer-imaging applications. This work is a major collaboration between the Frangioni Laboratory at the BIDMC and the Bawendi Laboratory at MIT.

   
Image button single photo emission copmuted tomography contrast agents SPECT is a commonly used nuclear medicine technique that provides clinicians with relatively high sensitivity disease detection. We have developed novel chemical processes to convert readily available and expensive sodium pertechnetate to a chemically-pure N-hydroxysuccinimide (NHS)-ester derivative. This derivative is produced in organic solvent, without the need for any high-performance liquid chromatography (HPLC), and can be used to label any small molecule, peptide, or protein, thus creating the next generation of SPECT contrast agents.
   
Image button of positron emission tomography contrast agents We have developed a robust chemical process for the conversion of readily available and relatively inexpensive 18FDG to a chemically pure, NHS-ester intermediate. This intermediate can be used to label small molecules, peptides, or proteins with F-18, thus creating the next generation of PET contrast agents.
   
Image button of magnetic resonance imaging contrast agents We are developing pre-labeling and post-labeling methods for the conjugation of lanthanide-labeled DOTA, and DOTA derivatives, to small molecules, peptides, and proteins. These conjugates could potentially produce the next generation of disease-targeted contrast agents for magnetic resonance imaging.
 
image of a molecule
 
Beth Israel Deaconess Medical Center Logo and Harvard Medical School Logo                                                                                                             
Link to Beth Israel Deaconess medical center home page and logo Beth Israel Deaconess Medical Center logo Harvard Medical School logo and link